[Federal Register Volume 70, Number 166 (Monday, August 29, 2005)]
[Proposed Rules]
[Page 50996]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-17163]


========================================================================
Proposed Rules
                                                Federal Register
________________________________________________________________________

This section of the FEDERAL REGISTER contains notices to the public of 
the proposed issuance of rules and regulations. The purpose of these 
notices is to give interested persons an opportunity to participate in 
the rule making prior to the adoption of the final rules.

========================================================================


Federal Register / Vol. 70, No. 166 / Monday, August 29, 2005 / 
Proposed Rules

[[Page 50996]]



DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[Docket No. DEA-269N]


Schedules of Controlled Substances: Placement of Embutramide Into 
Schedule III; Extension of Comment Period

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice of proposed rulemaking; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: The Drug Enforcement Administration (DEA) is extending the 
comment period and time to request a hearing on the Federal Register 
Notice of proposed rulemaking entitled ``Schedules of Controlled 
Substances: Placement of Embutramide into Schedule III'' published on 
July 29, 2005 (70 FR 43809).

DATES: The period for public comment that was to close on August 29, 
2005, will be extended to September 28, 2005.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-269P'' on all written and electronic correspondence. 
Written comments being sent via regular mail should be sent to the 
Deputy Administrator, Drug Enforcement Administration, Washington, DC 
20537, Attention: DEA Federal Register Representative/ODL. Written 
comments sent via express mail should be sent to the Deputy 
Administrator, Drug Enforcement Administration, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, 
VA 22301. Comments may be directly sent to DEA electronically by 
sending an electronic message to <a href="/cdn-cgi/l/email-protection#402425216e242936253233292f2e6e302f2c292339003533242f2a6e272f36"><span class="__cf_email__" data-cfemail="b6d2d3d798d2dfc0d3c4c5dfd9d898c6d9dadfd5cff6c3c5d2d9dc98d1d9c0">[email protected]</span></a>. 
Comments may also be sent electronically through http://www.regulations.gov using the electronic comment form provided on that 
site. An electronic copy of this document is also available at the 
http://www.regulations.gov Web site. DEA will accept electronic 
comments containing MS Word, WordPerfect, Adobe PDF, or Excel file 
formats only. DEA will not accept any file format other than those 
specifically listed here.

FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, 
Drug and Chemical Evaluation Section, Drug Enforcement Administration, 
Washington, DC 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: DEA published a Notice of Proposed 
Rulemaking (70 FR 43809) proposing the placement of embutramide into 
Schedule III of the Controlled Substances Act (CSA). The proposed 
scheduling action is based on a scientific and medical evaluation and 
recommendation by the Department of Health and Human Services and an 
evaluation of this and other information by DEA. On August 22, 2005, 
DEA received a request for an extension of the period in which to 
comment and request a hearing. The requestor indicated that the 
additional time is necessary to review the scientific articles and 
other information cited by DEA in support of its scheduling proposal. 
Upon consideration of this request, a thirty day extension of the time 
to comment and request a hearing is granted. This allows sufficient 
time for interested persons to evaluate and consider all relevant 
information and respond accordingly. Therefore, the comment period and 
time to request a hearing is extended to September 28, 2005. Comments 
must be received by the DEA on or before this date.

    Dated: August 24, 2005.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05-17163 Filed 8-26-05; 8:45 am]
BILLING CODE 4410-09-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>